Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 2;11(21):3463.
doi: 10.3390/cells11213463.

Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease: Should It Be Considered?

Simon Reider  1   2 , Lukas Binder  3 , Stefan Fürst  3 , Stefan Hatzl  4   5 , Andreas Blesl  3
Affiliations
Review

Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease: Should It Be Considered?

Simon Reider et al. Cells. .

Abstract

Hematopoietic stem cell transplantation (HSCT) is widely used in benign and malignant hematological diseases. During the last decade, HSCT, mainly autologous, also gained increasing attention in the treatment of refractory autoimmune diseases. Crohn's disease (CD) is an inflammatory bowel disease leading to transmural inflammation potentially affecting all parts of the luminal gastrointestinal tract. Despite improving therapeutic options, including various biologics, some patients are refractory to all lines of available conservative therapy, leading to increased morbidity and reduced quality of life. Apart from surgery, HSCT might be a reasonable treatment alternative for refractory CD patients. This review aims to describe the current role of HSCT in CD and discusses the procedure, the correct patient selection, the clinical efficacy from initial remission to following relapse rates, and complications of this treatment.

Keywords: Crohn’s disease; chemotherapy; hematopoietic stem cell transplantation; inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

Figures

Figure 1
Figure 1
Procedural steps of autologous hematopoietic stem cell transplantation in autoimmune diseases with used drug dosing in studies for Crohn’s disease. G-CSF = granulocyte colony-stimulating factor; ATG = anti-thymocyte globulin. Figure created with Biorender.com and Smart Servier Medical Art. Accessed on 9 September 2022.
See this image and copyright information in PMC

References

    1. Feuerstein J.D., Cheifetz A.S. Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo Clin. Proc. 2017;92:1088–1103. doi: 10.1016/j.mayocp.2017.04.010. - DOI - PubMed
    1. Torres J., Mehandru S., Colombel J.F., Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389:1741–1755. doi: 10.1016/S0140-6736(16)31711-1. - DOI - PubMed
    1. Nambu R., Warner N., Mulder D.J., Kotlarz D., McGovern D.P.B., Cho J., Klein C., Snapper S.B., Griffiths A.M., Iwama I., et al. A Systematic Review of Monogenic Inflammatory Bowel Disease. Clin. Gastroenterol. Hepatol. 2022;20:e653–e663. doi: 10.1016/j.cgh.2021.03.021. - DOI - PMC - PubMed
    1. Uhlig H.H., Schwerd T., Koletzko S., Shah N., Kammermeier J., Elkadri A., Ouahed J., Wilson D.C., Travis S.P., Turner D., et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147:990–1007.e1003. doi: 10.1053/j.gastro.2014.07.023. - DOI - PMC - PubMed
    1. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 2010;28:573–621. doi: 10.1146/annurev-immunol-030409-101225. - DOI - PMC - PubMed

MeSH terms